Mergers & Acquisitions ·
ENDRA amends merger deal with ASP Isotopes to remove classified board and supermajority vote requirements
NDRAENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. entered into a First Amendment to its Agreement and Plan of Merger with ASP Isotopes Inc., Noble Africa LLC, Renergen Limited, and Kruger Merger Sub LLC on October 1, 2026. The amendment removes the requirement for a classified board of directors and eliminates supermajority stockholder vote provisions in the Certificate of Incorporation. It revises the minimum cash closing condition to $3,800,002.59 to fund investor relations activities. Additionally, the amendment permits Renergen to increase its borrowing capacity under the ASPI Term Loan Facility from $80 million to up to $120 million via a fifth addendum, with a sixth addendum planned to raise it further to $200 million. The filing also includes amendments to Common Stock Purchase Warrants and Pre-Funded Common Stock Purchase Warrants issued to LHE LNG Holdings, removing the 4.99% beneficial ownership limitation on exercise. ENDRA Life Sciences Inc. operates in the life sciences industry, focusing on helium-3 medical imaging technologies.